Transactions
14
Insider / VERACYTE, INC.
Leite John
Chief Commercial Officer-CLIA at VERACYTE, INC.
- Company
- VERACYTE, INC.
- Ticker
- VCYT
- First filing on record
- October 3, 2025
- Latest trade on record
- September 21, 2026
- SEC filings
- EDGAR ↗
Leite John, Chief Commercial Officer-CLIA at VERACYTE, INC., has disclosed 14 transactions in VCYT since October 3, 2025: 0 purchases (0 open-market buys) and 11 sales, worth about $2.5M at the reported prices. The latest was filed September 22, 2026, 1 day after the trade.
Open-market buys
0
Sales
11
Avg. disclosure lag
2.1d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Leite John made no purchases and 10 sales worth $2.4M, plus 3 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Leite John has traded 1 stock on record; the largest by dollars is VCYT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 10 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 6 | 29,875 | $1.3M |
| F | Shares withheld for tax | 5 | 27,342 | $1.1M |
| A | Grant or award | 3 | 89,908 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 10 | 0 | 7 · $2.0M |
| 2025 | 4 | 0 | 4 · $424K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| VCYT | Sell S | September 21, 2026 | September 22, 2026 | 1d | 4,015 | $40 | $161K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell F | September 2, 2026 | September 4, 2026 | 2d | 3,961 | $45 | $178K | Form 4 ↗ | ||
| VCYT | Sell S | June 4, 2026 | June 4, 2026 | 0d | 13,975 | $50 | $700K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell F | June 2, 2026 | June 4, 2026 | 2d | 4,059 | $48 | $194K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Other A | March 6, 2026 | March 10, 2026 | 4d | 6,578 | — | — | Form 4 ↗ | ||
| VCYT | Other A | March 6, 2026 | March 10, 2026 | 4d | 36,181 | — | — | Form 4 ↗ | ||
| VCYT | Sell S | March 4, 2026 | March 6, 2026 | 2d | 5,260 | $35 | $185K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell F | March 2, 2026 | March 4, 2026 | 2d | 7,517 | $36 | $271K | Form 4 ↗ | ||
| VCYT | Sell F | February 26, 2026 | March 2, 2026 | 4d | 8,905 | $39 | $345K | Form 4 ↗ | ||
| VCYT | Other A | February 26, 2026 | March 2, 2026 | 4d | 47,149 | — | — | Form 4 ↗ | ||
| VCYT | Sell S | December 4, 2025 | December 4, 2025 | 0d | 1,278 | $48 | $61K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell F | December 2, 2025 | December 4, 2025 | 2d | 2,900 | $46 | $134K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell S | November 25, 2025 | November 26, 2025 | 1d | 2,808 | $50 | $140K | 10b5-1 plan | Form 4 ↗ | |
| VCYT | Sell S | October 1, 2025 | October 3, 2025 | 2d | 2,539 | $35 | $89K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 22, 2026 | Form 4 | 0001991536-26-000013 | 1 | published | EDGAR ↗ |
| September 4, 2026 | Form 4 | 0001991536-26-000011 | 1 | published | EDGAR ↗ |
| June 4, 2026 | Form 4 | 0001991536-26-000009 | 2 | published | EDGAR ↗ |
| March 10, 2026 | Form 4 | 0001991536-26-000008 | 2 | published | EDGAR ↗ |
| March 6, 2026 | Form 4 | 0001991536-26-000006 | 1 | published | EDGAR ↗ |
| March 4, 2026 | Form 4 | 0001991536-26-000004 | 1 | published | EDGAR ↗ |
| March 2, 2026 | Form 4 | 0001991536-26-000002 | 2 | published | EDGAR ↗ |
| December 4, 2025 | Form 4 | 0001991536-25-000008 | 2 | published | EDGAR ↗ |
| November 26, 2025 | Form 4 | 0001991536-25-000006 | 1 | published | EDGAR ↗ |
| October 3, 2025 | Form 4 | 0001991536-25-000004 | 1 | published | EDGAR ↗ |
Other insiders at VERACYTE, INC.
- McGuire Annie SVP, General Counsel 22 rows
- Chambers Rebecca Chief Financial Officer 17 rows
- JONES EVAN/ FA Director 14 rows
- Stapley Marc Chief Executive Officer 14 rows
- Febbo Phillip G. Chief Scientific & Med Officer 12 rows
- EASTHAM KARIN Director 11 rows
- Wygant Jonathan VP, Chief Accounting Officer 11 rows
- Bhanji Muna Director 5 rows
- EPSTEIN ROBERT S Director 5 rows
- Holstein Jens Director 5 rows
Everyone on file, with contracts and lobbying under the company's name: VERACYTE, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 10 | 14 | October 3, 2025 | September 22, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.